LA JOLLA, Calif.--Roy Whitfield, CEO of genomics and bioinformatics company Incyte Pharmaceuti cals, has joined the board of directors of Aurora Biosciences, a company here that designs and develops proprietary drug discovery systems, services, and technologies. Aurora's current collaborators include Bristol-Myers Squibb, Eli Lilly, Roche Bioscience, Sequana Therapeutics, and Allelix Bio pharmaceuticals.
Whitfield has served as CEO of Palo Alto-based Incyte since 1993. He has also been a director of the company since 1991 and was its president from 1991 until January of this year. Previously, he worked as a senior executive of Technicon Instruments and for the Boston Consulting Group.